DigestRedComo funciona
Red
/
Empresas
F.
No verificado

F. Hoffmann-La Roche Ltd

Sobre qué escribimos

Anuncios brevesFarmacéuticaPublicidad/Marketing/Medios de comunicación/Comunicación

175 Comunicados de prensa

Ver todos los comunicados de prensa
13/11/2026
Farmacéutica
Anuncios breves
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for systemic lupus erythematosus (SLE)
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
09/11/2026
Farmacéutica
Anuncios breves
Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
27/10/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
26/10/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
25/10/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
23/10/2026
Farmacéutica
Anuncios breves
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
21/10/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
21/10/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
18/10/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
15/10/2026
Farmacéutica
Anuncios breves
FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0